Handelsbanken Fonder’s Pacific Biosciences PACB Stock Holding History

Handelsbanken Fonder’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-53,800	Closed	-$202K	–	1574
2024 Q1	$202K	Hold	53,800	–	–	﹤0.01%	1509
2023 Q4	$528K	Buy	53,800 +17,700	+49%	+$145K	﹤0.01%	1119
2023 Q3	$301K	Hold	36,100	–	–	﹤0.01%	1306
2023 Q2	$480K	Hold	36,100	–	–	﹤0.01%	1083
2023 Q1	$418K	Hold	36,100	–	–	﹤0.01%	1090
2022 Q4	$295K	Hold	36,100	–	–	﹤0.01%	1254
2022 Q3	$210K	Hold	36,100	–	–	﹤0.01%	1421
2022 Q2	$160K	Buy	36,100 +6,700	+23%	+$40.7K	﹤0.01%	1529
2022 Q1	$268K	Sell	29,400 -10,900	-27%	-$125K	﹤0.01%	1560
2021 Q4	$825K	Buy	40,300 +1,300	+3%	+$31.4K	﹤0.01%	998
2021 Q3	$996K	Hold	39,000	–	–	0.01%	905
2021 Q2	$1.36M	Buy	39,000 +9,800	+34%	+$285K	0.01%	763
2021 Q1	$973K	Sell	29,200 -6,300	-18%	-$221K	0.01%	856
2020 Q4	$921K	Buy	+35,500	New	+$603K	0.01%	864

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Handelsbanken Fonder's PACB Position: Q2 2024 in Review

Handelsbanken Fonder sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 53,800 shares — an estimated $202K sold.

Handelsbanken Fonder first reported a position in PACB in Q4 2020 and held it in 14 quarters. The position peaked at $1.36M in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Handelsbanken Fonder reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Handelsbanken Fonder sold 53,800 Pacific Biosciences shares in Q2 2024, an estimated $202K.
Handelsbanken Fonder first reported a position in Pacific Biosciences in Q4 2020 and held it in 14 quarters.
Handelsbanken Fonder's Pacific Biosciences position peaked at $1.36M in Q2 2021.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.